If you are looking for a list of biotech stocks that you can buy, you're in luck. Below, I've included a comprehensive list of publicly traded companies engaged in biotech research and development. Among these companies are Incyte Corporation, Vertex Pharmaceuticals Inc., Anixa Biosciences, and Pitolisant.
CRISPR Therapeutics is a biotech company focusing on developing CRISPR/Cas9-based therapeutics. The company has a portfolio of therapeutic programs, including two aimed at preventing and treating type 1 diabetes and hemoglobinopathies. There is also a collaboration with Vertex Pharmaceuticals to develop treatments for beta-thalassemia and myotonic dystrophy type 1. In the past, CRISPR Therapeutics has received positive results in their sickle cell program, and management recently announced that they have a new product candidate in a clinical trial for transfusion-dependent beta-thalassemia. This treatment would lower hemolysis and anemia patients with beta-thalassemia must endure and improve their overall health. Incyte Corporation is a multinational biopharmaceutical company. The company manufactures medications in multiple therapeutic areas in Wilmington, DE. Its top-selling drug, Jakafi, is approved to treat steroid-refractory acute graft-versus-host disease. Other products in the pipeline include pemigatinib, an investigational cholangiocarcinoma treatment. As of the third quarter, Incyte generated total revenue of $813 million. Jakafi accounts for 80% of the company's revenue. The drug is approved for steroid-refractory acute marrow-versus-host disease, intermediate-risk myelofibrosis, and polycythemia vera. During the fourth quarter, Jakafi recorded sales of $466 million. Incyte has 21 compounds in various stages of development. Six of these compounds are in clinical trials. There are also several compounds in late-stage testing. Anixa Biosciences is a biotechnology company headquartered in San Jose, CA. The company's nifty little widgets are spread across the following sectors: vaccines, oncology, and diagnostics. It was formerly known as ITUS Corporation. In October 2018, the company changed its name to Anixa Biosciences. Anixa's most notable accomplishment is developing a novel CAR-T-based immuno-therapy drug. Aside from the company's newest endeavor, they have a solid portfolio of stalwart vaccines and other promising infectious disease agents. Some of their more esoteric offerings include a preventative ovarian cancer vaccine, a novel vaccine for triple-negative breast cancer, and many small molecules for a wide array of inherited metabolic diseases. The company develops antibody-drug conjugates (ADCs) for hematological and solid tumors. They employ monoclonal antibodies that target specific tumor antigens, combining them with pyrrolobenzodiazepine-based warheads. ADC Therapeutics has several PBD-based ADCs in development, including loncastuximab tesirine, camidanlumab tesirine, and ADCT-601. ADC Therapeutics' lead program, loncastuximab terrine, is in a phase 2 trial for patients with newly diagnosed diffuse large B-cell lymphoma. In addition to treating patients, the company conducts multiple tests with the drug and other agents. Its second drug, camidanlumab tesirine, targets CD25, a cancer cell membrane protein known to drive the growth of several different types of cancer. Pitolisant is a new medicine for the treatment of cataplexy in narcoleptic patients. It has been hailed as the first non-scheduled FDA-approved drug to treat the condition. The pharma is currently being evaluated for broader applications, including the more common idiopathic hypersomnia or pediatric narcolepsy. Pitolisant is a member of the H3 blocker class of medications. Developed by Bioprojet, the company is already commercializing the medicine in other countries. In 2016, pitolisant received a nod from the European Medicines Agency (EMA). Its effects are modest compared to other similar medicines, but it does have an impressive Kd value of 50+-4 pM. And, unlike other H3 agonists, pitolisant does not display amphetamine-like properties. Vertex Pharmaceuticals is a biotechnology company that develops small-molecule drugs for serious diseases. The company's products treat cancer, neurological disorders, infectious diseases, and inflammatory bowel disease. Its headquarters are in Boston, Massachusetts. It has offices in North America, Europe, and Latin America. Vertex was founded in 1989. At the time, its business was focused on inflammatory diseases and viral infections. In the 1990s, it developed protease inhibitors to treat HIV infection. By 2002, Vertex had a dozen drug products in development. Their goal was to build a robust drug discovery engine. They hired an expert in rational drug design, Navia.
0 Comments
|